• Alexi T., Hughes P., Faull R. and Williams C. (1998) 3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. NeuroReport 9, R57R64.
  • Araki T., Kato H. and Kogure K. (1991) Comparative protective effects of vinconate, baclofen, and pentobarbital against neuronal damage following repeated brief cerebral ischemia in the gerbil brain. Res. Exp. Med. (Berl) 191, 371378.
  • Borges C. R., Geddes T., Watson J. T. and Kuhn D. M. (2002) Dopamine biosynthesis is regulated by S-glutathionylation. Potential mechanism of tyrosine hydroxylast inhibition during oxidative stress. J. Biol. Chem. 277, 4829548302.
  • Brouillet E., Guyot M. C., Mittoux V., Altairac S., Condé F., Palfi S. and Hantraye P. (1998) Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70, 794805.
  • Fu Y., He F., Zhang S. and Jiao X. (1995) Consistent striatal damage in rats induced by 3-nitropropionic acid and cultures of arthrinium fungus. Neurotoxicol. Teratol. 17, 413418.
  • Herrera-Mundo N. and Sitges M. (2010) Mechanisms underlying striatal vulnerability to 3-nitropropionic acid. J. Neurochem. 114, 597605.
  • Jana S., Maiti A. K., Bagh M. B., Banerjee K., Das A., Roy A. and Chakrabarti S. (2007) Dopamine but not 3,4-dihydroxy phenyl acetic acid (DOPAC) inhibits brain respiratory chain activity bu autoxidation and mitochondria catalyzed oxidation to quinone products: Implications in Parkinson′s disease. Brain Res. 1139, 195200.
  • Khan F. H., Sen T., Maiti A. K., Jana S., Chatterjee U. and Chakrabarti S. (2005) Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: Implications for Parkinson′s disease. Biochim. Biophys. Acta 1741, 6574.
  • King G. A. (1987) Protective effects of vinpocetine and structurally related drugs on the lethal consequences of hypoxia in mice. Arch. Int. Pharmacodyn. Ther. 286, 299307.
  • Ludolph A. C., He F., Spencer P. S., Hammerstad J. and Sabri M. (1991) 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18, 492498.
  • Morinan A. and Garratt H. M. (1985) An improved fluorimetric assay for brain monoamine oxidase. J. Pharmacol. Methods 13, 213223.
  • Oláh V. A., Balla G., Balla J., Szabolcs A. and Karmazsin L. (1990) An in vitro study of the hydroxyl scavenger effect of Cavinton. Acta Paediatr. Hung. 30, 309316.
  • Osakada F., Hashino A., Kume T., Katsuki H., Kaneko S. and Akaike A. (2003) Neuroprotective effects of alpha-tocopherol on oxidative stress in rat striatal cultures. Eur. J. Pharmacol. 465, 1522.
  • Pereira C., Agostinho P. and Oliveira C. R. (2000) Vinpocetine attenuates the metabolic dysfunction induced by amyloid beta-peptides in PC12 cells. Free Radic. Res. 33, 497506.
  • Pérez-De La Cruz V., González-Cortés C., Pedraza-Chaverrí J., Maldonado P. D., Andrés-Martínez L. and Santamaría A. (2006) Protective effect of S-allylcysteine on 3-nitropropionic acid-induced lipid peroxidation and mitochondrial dysfunction in rat brain synaptosomes. Brain Res. Bull. 68, 379383.
  • Reynolds D., Carter R. and Morton A. (1998) Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci. 23, 1011610127.
  • Santos M. S., Duarte A. I., Moreira P. I. and Oliveira C. R. (2000) Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic. Res. 32, 5766.
  • Sitges M. and Nekrassov V. (1999) Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation. Neurochem. Res. 24, 15851591.
  • Sitges M., Chiu L. M. and Nekrassov V. (2007) Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 52, 598605.
  • Sitges M., Aldana B. I., Chiu L. M. and Nekrassov V. (2009) Characterization of phenytoin, carbamazepine, vinpocetine and clorgyline simultaneous effects on sodium channels and catecholamine metabolism in rat striatal nerve endings. Neurochem. Res. 34, 470479.
  • Trejo F., Nekrassov V. and Sitges M. (2001) Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res. 909, 5967.
  • Tretter L. and Adam-Vizi V. (1998) The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2 + ]i rise in synaptosomes. NeuroReport 9, 18491853.
  • Villarán R., Tomás-Camardiel M., de Pablos R., Santiago M., Herrera A., Navarro A., Machado A. and Cano J. (2008) Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production. Neurotoxicology 29, 244258.
  • Wang X. and Quinn P. J. (1999) Vitamin E and its function in membranes. Prog. Lipid Res. 38, 309336.